217 related articles for article (PubMed ID: 15757449)
21. Functional analysis of the p53 pathway in response to ionizing radiation in uveal melanoma.
Sun Y; Tran BN; Worley LA; Delston RB; Harbour JW
Invest Ophthalmol Vis Sci; 2005 May; 46(5):1561-4. PubMed ID: 15851551
[TBL] [Abstract][Full Text] [Related]
22. Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers.
Sabbah M; Emami S; Redeuilh G; Julien S; Prévost G; Zimber A; Ouelaa R; Bracke M; De Wever O; Gespach C
Drug Resist Updat; 2008; 11(4-5):123-51. PubMed ID: 18718806
[TBL] [Abstract][Full Text] [Related]
23. [p53 as a molecular target for cancer therapy].
Ishioka C; Osada M; Gamo M; Kanamaru R
Gan To Kagaku Ryoho; 1997 Dec; 24(15):2207-12. PubMed ID: 9422063
[TBL] [Abstract][Full Text] [Related]
24. Reactivation of mutant p53: molecular mechanisms and therapeutic potential.
Selivanova G; Wiman KG
Oncogene; 2007 Apr; 26(15):2243-54. PubMed ID: 17401433
[TBL] [Abstract][Full Text] [Related]
25. The p53 tumour suppressor gene.
Steele RJ; Thompson AM; Hall PA; Lane DP
Br J Surg; 1998 Nov; 85(11):1460-7. PubMed ID: 9823903
[TBL] [Abstract][Full Text] [Related]
26. PHTS, a novel putative tumor suppressor, is involved in the transformation reversion of HeLaHF cells independently of the p53 pathway.
Yu DH; Fan W; Liu G; Nguy V; Chatterton JE; Long S; Ke N; Meyhack B; Bruengger A; Brachat A; Wong-Staal F; Li QX
Exp Cell Res; 2006 Apr; 312(6):865-76. PubMed ID: 16413018
[TBL] [Abstract][Full Text] [Related]
27. Overcoming apoptosis deficiency of melanoma-hope for new therapeutic approaches.
Eberle J; Kurbanov BM; Hossini AM; Trefzer U; Fecker LF
Drug Resist Updat; 2007 Dec; 10(6):218-34. PubMed ID: 18054518
[TBL] [Abstract][Full Text] [Related]
28. Molecularly targeted therapies for malignant gliomas: advances and challenges.
Penas-Prado M; Gilbert MR
Expert Rev Anticancer Ther; 2007 May; 7(5):641-61. PubMed ID: 17492929
[TBL] [Abstract][Full Text] [Related]
29. Rational targeting of Notch signaling in cancer.
Rizzo P; Osipo C; Foreman K; Golde T; Osborne B; Miele L
Oncogene; 2008 Sep; 27(38):5124-31. PubMed ID: 18758481
[TBL] [Abstract][Full Text] [Related]
30. Molecular genetic analysis of p53 intratumoral heterogeneity in human astrocytic brain tumors.
Ren ZP; Olofsson T; Qu M; Hesselager G; Soussi T; Kalimo H; Smits A; Nistér M
J Neuropathol Exp Neurol; 2007 Oct; 66(10):944-54. PubMed ID: 17917588
[TBL] [Abstract][Full Text] [Related]
31. Anti-P53 antibodies in Brazilian brain tumor patients.
Fonseca RF; Kawamura MT; Oliveira JA; Teixeira A; Alves G; Carvalho Mda G
Genet Mol Res; 2003 Jun; 2(2):185-90. PubMed ID: 14966683
[TBL] [Abstract][Full Text] [Related]
32. Human tumor suppressor p53 and DNA viruses.
Collot-Teixeira S; Bass J; Denis F; Ranger-Rogez S
Rev Med Virol; 2004; 14(5):301-19. PubMed ID: 15334538
[TBL] [Abstract][Full Text] [Related]
33. Molecular pathogenesis of adult brain tumors and the role of stem cells.
Sauvageot CM; Kesari S; Stiles CD
Neurol Clin; 2007 Nov; 25(4):891-924, vii. PubMed ID: 17964020
[TBL] [Abstract][Full Text] [Related]
34. Signaling from p53 to NF-kappaB determines the chemotherapy responsiveness of neuroblastoma.
Armstrong MB; Bian X; Liu Y; Subramanian C; Ratanaproeksa AB; Shao F; Yu VC; Kwok RP; Opipari AW; Castle VP
Neoplasia; 2006 Nov; 8(11):967-77. PubMed ID: 17132229
[TBL] [Abstract][Full Text] [Related]
35. [The p53 gene and protein in 2005: new results, promising opportunities].
Szoke D; Sipos F; Spisák S; Molnár B; Tulassay Z
Orv Hetil; 2005 Jul; 146(30):1587-94. PubMed ID: 16136736
[TBL] [Abstract][Full Text] [Related]
36. Mutant p53: the loaded gun.
Selivanova G
Curr Opin Investig Drugs; 2001 Aug; 2(8):1136-41. PubMed ID: 11892926
[TBL] [Abstract][Full Text] [Related]
37. Protein p53--structure, function, and possible therapeutic implications.
Batinac T; Gruber F; Lipozencić J; Zamolo-Koncar G; Stasić A; Brajac I
Acta Dermatovenerol Croat; 2003 Dec; 11(4):225-30. PubMed ID: 14670223
[TBL] [Abstract][Full Text] [Related]
38. Current strategies to target p53 in cancer.
Chen F; Wang W; El-Deiry WS
Biochem Pharmacol; 2010 Sep; 80(5):724-30. PubMed ID: 20450892
[TBL] [Abstract][Full Text] [Related]
39. Reversible dysfunction of wild-type p53 following homeodomain-interacting protein kinase-2 knockdown.
Puca R; Nardinocchi L; Gal H; Rechavi G; Amariglio N; Domany E; Notterman DA; Scarsella M; Leonetti C; Sacchi A; Blandino G; Givol D; D'Orazi G
Cancer Res; 2008 May; 68(10):3707-14. PubMed ID: 18483253
[TBL] [Abstract][Full Text] [Related]
40. [Regulation of the cell cycle and the development of cancer: therapeutic prospects].
Peralta-Zaragoza O; Bahena-Román M; Díaz-Benítez CE; Madrid-Marina V
Salud Publica Mex; 1997; 39(5):451-62. PubMed ID: 9424727
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
